União Europeia -
finlandês -
EMA (European Medicines Agency)
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuskulaarinen estäminen - kaikki muut terapeuttiset tuotteet - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
União Europeia -
finlandês -
EMA (European Medicines Agency)
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulaarinen estäminen - kaikki muut terapeuttiset tuotteet - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Finlândia -
finlandês -
Fimea (Suomen lääkevirasto)
fampridine stada 10 mg depottabletti
stada arzneimittel ag - fampridine - depottabletti - 10 mg - fampridiini
Finlândia -
finlandês -
Fimea (Suomen lääkevirasto)
duloxetine accordpharma 40 mg enterokapseli, kova
accord healthcare b.v. - duloxetine hydrochloride - enterokapseli, kova - 40 mg - duloksetiini
Finlândia -
finlandês -
Fimea (Suomen lääkevirasto)
duloxetine accordpharma 20 mg enterokapseli, kova
accord healthcare b.v. - duloxetine hydrochloride - enterokapseli, kova - 20 mg - duloksetiini
União Europeia -
finlandês -
EMA (European Medicines Agency)
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - neuromuskulaarinen estäminen - sugammadeksi - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
União Europeia -
finlandês -
EMA (European Medicines Agency)
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskulaarinen estäminen - kaikki muut terapeuttiset tuotteet - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.